Akademik Veri Yönetim Sistemi
KÖMÜR S. , KURTARAN B. , İNAL A. S. , PULLUKÇU H., ULU A. , Kuscu F. , et al.
HEPATITIS MONTHLY, cilt.15, 2015 (SCI İndekslerine Giren Dergi)
Background: In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1.